ArticleJournal of gynecologic oncology2020
Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007-2014.
Article in Journal of gynecologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Nanoparticles in gynecologic cancers: a bibliometric and visualization analysis.Frontiers in oncology · 2024Pooled it
- Robotic uterine transposition for fertility preservation in patients undergoing pelvic radiotherapy: a narrative review of surgical evolution, technical strategies, and emerging evidence.Journal of robotic surgery · 2026Review
- Trends in the cost of ovarian cancer across phases of care and surgical years in Korea.Journal of gynecologic oncology · 2026Article
- Spectrum of gynecologic malignancies in Northeastern Nigeria.Frontiers in oncology · 2025Article
- A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers.Oncology and therapy · 2024Review
- Cost of care associated with utilization of telehealth in clinical trials.Gynecologic oncology reports · 2024Article
- Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies.International journal of molecular sciences · 2024Review
- Symptom burden, palliative care knowledge, and palliative care needs in advanced gynecological cancer patients in Korea.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- The impact of pathogenicSAGE open medicine · 2024Article
- Beyond Sterilization: A Comprehensive Review on the Safety and Efficacy of Opportunistic Salpingectomy as a Preventative Strategy for Ovarian Cancer.Current oncology (Toronto, Ont.) · 2023Review
- Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies:JACC. CardioOncology · 2023Review
- Economic Burden of Cervical Cancer in Bulgaria.International journal of environmental research and public health · 2023Article
- The Burden of Out-of-Pocket Expenditure Related to Gynaecological Cancer in Malaysia.Healthcare (Basel, Switzerland) · 2022Article
- Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022Article
- Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer.Advances in therapy · 2022Article
- The Chinese version of the Revised Dyadic Adjustment Scale for gynaecological cancer patients and their partners: Translation and psychometric evaluation.Asia-Pacific journal of oncology nursing · 2022Article
- Challenges in the implementation of electronic systems for patient report of symptoms in oncology: a scoping review.Journal of hospital management and health policy · 2021Article
- Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.Gynecologic oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study estimated nationally representative medical expenditures of gynecologic cancers, described treatment patterns and assessed key risk factors associated with the economic burden in the United States.
methodsA retrospective repeated measures design was used to estimate the effect of gynecologic cancers on medical expenditures and utilization among women. Data were extracted from the Medical Expenditure Panel Survey (weighted sample of 609,787 US adults) from 2007 to 2014. Using the behavioral model of health services utilization, characteristics of cancer patients were examined and compared among uterine, cervical, and ovarian cancer patients. Multivariable linear regression models were conducted on medical expenditure with a prior logarithmic transformation.
resultsThe estimated annual medical expenditure attributed to gynecologic cancers was $3.8 billion, with an average cost of $6,293 per patient. The highest annual cost per person was ovarian cancer ($13,566), followed by uterine cancer ($6,852), and cervical cancer ($2,312). The major components of medical costs were hospital inpatient stays (53%, $2.03 billion), followed by office-based visits (15%, $559 million), and outpatient visits (13%, $487 million). Two key prescription expenditures were antineoplastic hormones (10.3%) and analgesics (9.2%). High expenditures were significantly associated with being a married woman (p<0.001), having private health insurance (p<0.001), being from a low- and middle-income family (p<0.001), or living in the Midwest or the South (p<0.001).
conclusionThe key risk factors and components were well described for the economic burden of gynecologic cancers. With a growing population of cancer patients, efforts to reduce the burden of gynecologic cancers are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.